Clinical trials
Unresectable Skin Squamous Cell Carcinoma clinical trials
Below are recruiting unresectable skin squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 101 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07554521RecruitingPhase 2
Tislelizumab Plus Chemotherapy for Advanced Stomach or Esophageal Cancer
This study tests a combination of two drugs—tislelizumab (an immunotherapy) and chemotherapy—to treat advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be surgically removed. The trial focuses on recruiting patients from racial and ethnic minority communities to ensure the treatment is studied in diverse populations.
Cerritos, CaliforniaAges 18 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT06239220RecruitingPhase 2
Combination immunotherapy for advanced head and neck cancer
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
Boston, MassachusettsAges 18 years+ - NCT05136196RecruitingPhase 2
Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
Phoenix, ArizonaAges 18 years+ - NCT07426484RecruitingPhase 4
Testing cosibelimab for advanced skin cancer in specific patients
This trial tests an immunotherapy drug called cosibelimab for patients with advanced cutaneous squamous cell carcinoma who have either had a kidney transplant or have a blood cancer like lymphoma or myeloma. The goal is to see if it can shrink tumors when surgery or radiation is not an option.
Boston, MassachusettsAges 18 years+ - NCT05515315RecruitingPhase 2
Immunotherapy plus chemo then chemoradiation for esophageal cancer
This Phase 2 study tests whether adding tislelizumab (an immunotherapy drug) to chemotherapy before a combined course of chemotherapy and radiation can better treat locally advanced, non-surgable esophageal squamous cell cancer. It’s for adults who cannot have surgery and may help shrink the cancer and improve control of the disease.
Fuzhou, FujianAges 18–70 - NCT05085496RecruitingPhase 1
Radiation plus atezolizumab for advanced skin cancer
This Phase 1 trial studies adding atezolizumab (an immune therapy) to radiation for people with hard-to-remove or borderline-resectable cutaneous squamous cell carcinoma (cSCC). The goal is to see whether this combination can better control the cancer and whether the treatment is safe.
Duarte, CaliforniaAges 18 years+ - NCT07645690RecruitingEarly Phase 1
CD70 CAR-T Cell Therapy for Advanced Kidney Cancer
This early-stage trial tests a new type of cell therapy called CD70 CAR-T for advanced kidney cancer (clear cell renal cell carcinoma) that has spread or cannot be surgically removed. The therapy uses cells from your own immune system that are genetically modified to recognize and attack cancer cells.
BeijingAges 18–75 - NCT07545967RecruitingPhase 1
Re-radiation and Chidamide for Recurrent Head and Neck Cancer
This trial tests combining re-radiation (radiation therapy given a second time) with a drug called chidamide to treat head and neck cancer that has come back after previous radiation. The goal is to see if this combination can help patients whose cancer cannot be removed by surgery or who cannot have surgery.
Chengdu, SichuanAges 18–75 - NCT06567314RecruitingPhase 2
Study of Ivonescimab for advanced skin or prostate cancer
This study tests a new immunotherapy medicine, ivonescimab, in people with advanced skin cancer or advanced prostate cancer. It looks at how safe and effective the drug is.
Houston, TexasAges 18 years+ - NCT07215988Recruiting
Studying insurance for skin cancer treatment
This study looks at how insurance covers immunotherapy given before surgery for certain skin cancers. It includes people with Merkel cell, mucosal melanoma, basal cell, or other rare skin cancers who are planning to have surgery.
Columbus, OhioAges 18 years+ - NCT07156227RecruitingPhase 1
Testing camonsertib with radiation for returning head and neck cancer
This study tests whether adding the drug camonsertib to radiation therapy can help people whose head and neck cancer has come back in a spot that was already treated with radiation. Camonsertib is an experimental drug that may help radiation work better.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06644781RecruitingPhase 3
Study of Ifinatamab Deruxtecan for advanced esophageal cancer
This trial tests a new drug, Ifinatamab Deruxtecan, for people with advanced esophageal squamous cell carcinoma that has worsened after standard treatments. It aims to see if it can help shrink or slow the cancer.
Phoenix, ArizonaAges 18 years+ - NCT04754321RecruitingPhase 1
Test immunotherapy with salvage surgery and IORT for head and neck cancer
This Phase 1 trial tests a new plan that combines immunotherapy with surgery, plus a targeted radiation treatment called IORT. It is for people whose head and neck squamous cell cancer has come back or never fully went away and can be operated on. The goal is to shrink or control the cancer and see how safe the approach is.
Columbus, OhioAges 18 years+ - NCT05419089RecruitingPhase 2
Testing robotic surgery for HPV-related throat cancer patients
This Phase 2 trial studies a robotic surgery approach for certain HPV-related throat cancers, using HPV blood tests before and after surgery to guide care. If your cancer is HPV-related and your HPV blood test results match the trial targets, you may be able to join and help improve treatment for future patients.
Paramus, New JerseyAges 18 years+ - NCT03521830RecruitingPhase 2
Nivolumab and other immunotherapy for advanced basal cell skin cancer
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
Baltimore, MarylandAges 18 years+ - NCT04224389Recruiting
Radiation plus throat surgery for early tonsil or tongue-base cancer
This study compares ways of treating early squamous cell cancer in the tonsil or the tongue base, using either radiation therapy, transoral (through-the-mouth) surgery, or both. It aims to see which approach works best while keeping cancer under control.
Villejuif, Val De MarneAges 18 years+ - NCT04534205RecruitingPhase 2/Phase 3
Testing BNT113 plus pembrolizumab versus pembrolizumab alone
This trial studies whether adding BNT113 to pembrolizumab works better and is safe for people with HPV16-positive head and neck cancer that can’t be cured with local treatments. It also compares outcomes to pembrolizumab alone, specifically for tumors that show PD-L1 in testing.
Los Angeles, CaliforniaAges 18 years+ - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Gilbert, ArizonaAges 18 years+ - NCT05047094Recruiting
DaRT radiation plus pembrolizumab for head and neck cancer
This trial tests whether a targeted internal radiation treatment (DaRT) combined with pembrolizumab (an immune therapy) can shrink recurrent or metastatic head and neck squamous cell cancer that cannot be fully removed with surgery. It may help by making cancer more visible to the immune system while delivering localized radiation to a tumor area.
JerusalemAges 18 years+ - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
Birmingham, AlabamaAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05144698RecruitingPhase 1/Phase 2
RAPA-201 cell therapy for certain advanced lung and head cancers
This Phase 1/2 trial tests RAPA-201, a personalized immune cell treatment made from your own T cells, for advanced solid tumors. It may help people whose cancer has come back after standard treatment and after an anti–PD-1/PD-L1 antibody.
Hackensack, New JerseyAges 18 years+
Hear when a new Unresectable Skin Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for unresectable skin squamous cell carcinoma?
- Yes. Clin2 currently lists 101 recruiting unresectable skin squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a unresectable skin squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a unresectable skin squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.